Current Cancer Therapy Reviews

Kurt S. Zaenker
Institute of Immunology and Experimental Oncology University Witten/Herdecke
Stockumerstraße 10, 58448 Witten
Germany

Back

Approaches Used in Immunotherapy for Prostate Cancer

Author(s): Guru Sonpavde.

Abstract:

The approval of sipuleucel-T for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer (CRPC) has validated immunotherapy, in general, as a valid approach for this disease. Multiple novel immune based approaches including adenoviral-based vector delivering targeted antigen, DNAbased vaccination, listeria-based vaccination, pox-viral based approach, immune checkpoint blockade and radioimmunoconjugates appear promising. In concert with the development of new immunotherapeutics, the development of optimal intermediate endpoints for clinical efficacy, measures of an optimal immune response and biomarkers predictive for benefit are warranted. We briefly review emerging immunotherapeutic approaches to treat patients with CRPC.

Keywords: Immunotherapy, Castration resistant, Prostate cancer, Sipuleucel-T, Immunotherapy, Novel

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 8
ISSUE: 4
Year: 2012
Page: [238 - 244]
Pages: 7
DOI: 10.2174/1573394711208040238
Price: $58